Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV randomized, multicenter, open-label study to compare the safety, tolerability and efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) bid vs Combivir (lamivudine 150mg and zidovudine 300mg) bid plus atazanavir 400mg qd in antiretroviral naive HIV-1 infected subjects over 48 weeks.

Next Previous
Trial Profile

A phase IV randomized, multicenter, open-label study to compare the safety, tolerability and efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) bid vs Combivir (lamivudine 150mg and zidovudine 300mg) bid plus atazanavir 400mg qd in antiretroviral naive HIV-1 infected subjects over 48 weeks.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir (Primary) ; Lamivudine/zidovudine (Primary) ; Lamivudine/zidovudine/abacavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ACTION
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 15 Oct 2008 Actual start date changed from May 2004 to Apr 2004 as reported by Clinicaltrials.gov
    • 17 Jul 2007 Status change from in progress to completed
    • 19 Oct 2005 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top